Literature DB >> 9324624

[Palliative therapy of carcinomas of the biliary system].

C Lersch1, M Classen.   

Abstract

CARCINOMA OF THE GALLBLADDER: Only patients suffering from advanced disease have symptoms, that is pain, jaundice, weight loss. Mean 5-year survival rate tends to be lower than 5%. Tumors can be resected with negative margins in 15 to 25% of the patients. Obstructive jaundice can be managed with endoscopic biliary stent in 84% of the patients. After radiotherapy tumor regression is observed in 80% of the patients. Their mean survival time is 10 months. CHOLANGIOCARCINOMAS: More than 90% of the patients present with jaundice. At the time of presentation, 50% of the patients already have metastases to lymph nodes. Mean total survival time of all patients is 12 months. Surgical resection can successfully be performed in 30 to 40% of the patients suffering from proximal cholangiocarcinomas. Distal unresectable tumors are best palliated with an endoscopically placed stent in 97.5% of the patients. Patients having undergone radiotherapy will have a mean survival time of 9 to 12 months. There is a 12% response rate after chemotherapy with single agents and one of 23% after combined regimens. Intraarterial application of chemotherapy results in 44% response rate.
CONCLUSION: Carcinomas of the biliary tract are often diagnosed at advanced inoperable stages. Patients quality of life can be ameliorated by palliative treatment, i.e. biliary stents, radio-, chemotherapy. Mean survival time does normally not exceed 1 year.

Entities:  

Mesh:

Year:  1997        PMID: 9324624     DOI: 10.1007/BF03042570

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  47 in total

1.  Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer.

Authors:  M Colleoni; M Di Bartolomeo; A Di Leo; N Zilembo; C Carnaghi; A Pandolfi; L Rimassa; S Artale; E Bajetta
Journal:  Eur J Cancer       Date:  1995-12       Impact factor: 9.162

2.  Value of endobiliary brush cytology and biopsies for the diagnosis of malignant bile duct stenosis: results of a prospective study.

Authors:  T Ponchon; P Gagnon; F Berger; M Labadie; A Liaras; A Chavaillon; R Bory
Journal:  Gastrointest Endosc       Date:  1995-12       Impact factor: 9.427

3.  Role of radiation after operative palliation in cancer of the proximal bile ducts.

Authors:  M K Grove; R E Hermann; D P Vogt; T A Broughan
Journal:  Am J Surg       Date:  1991-04       Impact factor: 2.565

4.  Invasive growth patterns of hepatic hilar ductal carcinoma. A histologic analysis of 18 surgical cases.

Authors:  S Hayashi; M Miyazaki; Y Kondo; N Nakajima
Journal:  Cancer       Date:  1994-06-15       Impact factor: 6.860

5.  Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study.

Authors:  M Kajanti; S Pyrhönen
Journal:  Am J Clin Oncol       Date:  1994-06       Impact factor: 2.339

6.  Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology.

Authors:  K Ohashi; Y Nakajima; H Kanehiro; M Tsutsumi; J Taki; Y Aomatsu; A Yoshimura; S Ko; T Kin; K Yagura
Journal:  Gastroenterology       Date:  1995-11       Impact factor: 22.682

7.  Intraoperative radiotherapy for unresectable cholangiocarcinoma--the Mayo Clinic experience.

Authors:  J R Monson; J H Donohue; L L Gunderson; D M Nagorney; C E Bender; H S Wieand
Journal:  Surg Oncol       Date:  1992-08       Impact factor: 3.279

8.  Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer.

Authors:  S W Hall; R S Benjamin; W K Murphy; M Valdivieso; G P Bodey
Journal:  Cancer       Date:  1979-12       Impact factor: 6.860

9.  Endoscopic biliary endoprosthesis for palliation of gallbladder carcinoma.

Authors:  J C Vij; A Govil; A Chaudhary; R Gulati; S Mehta; S Ganguli
Journal:  Gastrointest Endosc       Date:  1996-02       Impact factor: 9.427

10.  Malignant obstruction of the common bile duct: long-term results of Gianturco-Rosch metal stents used as initial treatment.

Authors:  J R Mathieson; R F McLoughlin; P L Cooperberg; C C Prystai; S N Stordy; J K MacFarlane; N Schmidt
Journal:  Radiology       Date:  1994-09       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.